NCT06218303 2026-03-12
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
University of Pittsburgh
Phase 1 Recruiting
Clinical Trials
14 trialsNCT05307705 2026-03-02
PIKASSO-01
Eli Lilly and Company
Phase 1 Active not recruiting
NCT02057133 2026-01-26
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Eli Lilly and Company
Phase 1 Active not recruiting
NCT02779751 2026-01-26
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04556773 2025-12-17
DB-08
AstraZeneca
Phase 1 Active not recruiting
NCT07163481 2025-09-16
SoGreat
Hunan Cancer Hospital
Phase 1 Not yet recruiting
NCT03099174 2025-06-24
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT03554044 2025-05-21
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT04316169 2022-12-23
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
Medical College of Wisconsin
Phase 1 Withdrawn
NCT01197170 2021-01-22
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02093351 2019-10-02
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
AstraZeneca
Phase 1 Completed
NCT01597193 2019-05-08
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Pfizer
Phase 1 Completed
NCT01344031 2018-07-23
MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00588003 2015-12-24
Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed